Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir Parekh

Showing results (131-140 of 162) with videos related to

Pageof 17
Sort By:
Communications Biology|November 26, 2022
A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurementsRobert J Kimmerling, Mark M Stevens, Selim Olcum, et al.
Blood|November 3, 2022
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapyOliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, et al.
Blood|September 4, 2015
Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infectionThomas H Price, Michael Boeckh, Ryan W Harrison, et al.
Blood Neoplasia|June 24, 2025
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myelomaRudra P Dutta, Santiago Thibaud, Violetta Leshchenko, et al.
Cell Stem Cell|February 21, 2017
Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable LeukemiaAndriana G Kotini, Chan-Jung Chang, Arthur Chow, et al.
Blood|July 4, 2012
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterationsBritta Will, Li Zhou, Thomas O Vogler, et al.
Leukemia & Lymphoma|August 20, 2020
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myelomaOliver Van Oekelen, Samir Parekh, Hearn J Cho, et al.
Blood Advances|August 27, 2025
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1Carolina Schinke, Paula Rodriguez-Otero, Niels W C J van de Donk, et al.
The Lancet. Haematology|December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 studyKieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.
Blood Advances|May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myelomaMateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, et al.
Pageof 17

Showing results (131-140 of 162) with videos related to

Sort By:
Pageof 17
Communications Biology|November 26, 2022
A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurementsRobert J Kimmerling, Mark M Stevens, Selim Olcum, et al.
Blood|November 3, 2022
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapyOliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, et al.
Blood|September 4, 2015
Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infectionThomas H Price, Michael Boeckh, Ryan W Harrison, et al.
Blood Neoplasia|June 24, 2025
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myelomaRudra P Dutta, Santiago Thibaud, Violetta Leshchenko, et al.
Cell Stem Cell|February 21, 2017
Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable LeukemiaAndriana G Kotini, Chan-Jung Chang, Arthur Chow, et al.
Blood|July 4, 2012
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterationsBritta Will, Li Zhou, Thomas O Vogler, et al.
Leukemia & Lymphoma|August 20, 2020
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myelomaOliver Van Oekelen, Samir Parekh, Hearn J Cho, et al.
Blood Advances|August 27, 2025
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1Carolina Schinke, Paula Rodriguez-Otero, Niels W C J van de Donk, et al.
The Lancet. Haematology|December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 studyKieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.
Blood Advances|May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myelomaMateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, et al.
Pageof 17